822 related articles for article (PubMed ID: 30442276)
21. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
22. Age dependency of EQ-5D-Youth health states valuations on a visual analogue scale.
Retra JGA; Essers BAB; Joore MA; Evers SMAA; Dirksen CD
Health Qual Life Outcomes; 2020 Dec; 18(1):386. PubMed ID: 33308228
[TBL] [Abstract][Full Text] [Related]
23. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
[TBL] [Abstract][Full Text] [Related]
24. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D.
Feng Y; Herdman M; van Nooten F; Cleeland C; Parkin D; Ikeda S; Igarashi A; Devlin NJ
Qual Life Res; 2017 Aug; 26(8):2067-2078. PubMed ID: 28343350
[TBL] [Abstract][Full Text] [Related]
25. [Development of the German version of EQ-5D-Y-5L to measure health-related quality of life in children and adolescents: Identification of response labels and pilot testing].
Kreimeier S; Greiner W
Z Evid Fortbild Qual Gesundhwes; 2019 Aug; 144-145():24-34. PubMed ID: 31378708
[TBL] [Abstract][Full Text] [Related]
26. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
27. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
28. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
29. In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.
Lipman SA; Essers BAB; Finch AP; Sajjad A; Stalmeier PFM; Roudijk B
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):181-192. PubMed ID: 36255560
[TBL] [Abstract][Full Text] [Related]
30. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
32. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
Stevens K; Brazier J; Rowen D
Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
[TBL] [Abstract][Full Text] [Related]
33. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?
Feng Y; Devlin N; Herdman M
Health Qual Life Outcomes; 2015 Oct; 13():171. PubMed ID: 26489956
[TBL] [Abstract][Full Text] [Related]
34. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
35. Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents.
Åström M; Rolfson O; Burström K
Appl Health Econ Health Policy; 2022 May; 20(3):383-393. PubMed ID: 35083734
[TBL] [Abstract][Full Text] [Related]
36. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
[TBL] [Abstract][Full Text] [Related]
37. Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
Mott DJ; Shah KK; Ramos-Goñi JM; Devlin NJ; Rivero-Arias O
Med Decis Making; 2021 Jul; 41(5):584-596. PubMed ID: 33733920
[TBL] [Abstract][Full Text] [Related]
38. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
39. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
40. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
